ZYME today

$28.45-$0.62 (-2.13%)close Nov 12, 2026

Trend

DailyUptrend (confirmed)

4 hourLeaning Bearish

1 hourStrong Bearish

15 minStrong Bearish

5 minDescending Triangle

Daily trend turns down below $24.60

Key levels

Resistance$31.49

Resistance$30.18

Support$28.40

Support$27.02

About Zymeworks

Zymeworks is a biotechnology company that develops antibody-based therapies for cancer, inflammation, and autoimmune diseases. It uses its Azymetric, ZymeLink, and EFECT platforms to create bispecific antibodies and antibody-drug conjugates. Its lead approved product, Ziihera (zanidatamab), is licensed to Jazz Pharmaceuticals and BeOne Medicines for different territories. The company also has partnerships with Bristol-Myers Squibb, GSK, Daiichi Sankyo, Johnson & Johnson, and Merck, and operates in the United States and Canada.

Based on the company's 10-K filed Mar 2, 2026.

Nasdaq · Healthcare

Zymeworks Inc. (ZYME)

$28.45-0.62 (-2.13%)

STRONG_BUYGrade: ARisk: LOW

1D 5D1M1Y 5Y MaxSign up for all timeframes

High29.03

Low28.25

Open28.92

Volume17K

Avg Vol795K

VWAP28.77

30d High31.46

30d Low24.77

30d Chg+13.12%

See full chart with real-time data

What Is the Price Target for ZYME?

SEPT Low Target

$32.00

SEPT Mid Target

$39.00

SEPT High Target

$55.00

Analyst Consensus

$39.00

Current: $28.92Upside: +34.9%Confidence: 85%Method: Analyst Consensus

Is ZYME a Buy or Sell Right Now?

Investability Score

STRONG_BUY12-18 months

News summary · last 30 days

Critical news

Nov 9HIGHEarnings: growth/beat

Thesis

•Revenue growing 38.9% YoY with ACCELERATING trend — accelerating momentum.

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ZYME.

Start Free Trial →

Is ZYME Overvalued or Undervalued?

Valuation Verdict

OVERVALUED

Methods Used

P/E Forward, P/B, Analyst Consensus

Fair Value

$29.87

Moat Score

NONE

6/9

Piotroski Score

12.9

Altman Z-Score

What Is Smart Money Doing with ZYME?

Insider Signal

SELLING

0 buys / 5 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

HIGH

Signal: HIGH_SHORT_INTEREST

Recent Insider Activity

Name	Title	Type	Shares	Value	Date
Schayowitz Adam	officer	Buy	37,037	-	Oct 9, 2026
Schayowitz Adam	officer	Sale	13,832	$358K	Oct 9, 2026

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

ZYME Growth Story

Revenue YoY

38.9%

3yr Revenue CAGR

-36.4%

EPS Growth YoY

33.33%

FCF Growth YoY

69.2%

Revenue Trend

ACCELERATING

Dark Pool Trades for ZYME

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for ZYME, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

Time	Price	Size	Value	Side
22:25:52	$29.07	81,700	$$2.4M	SELL
21:00:47	$29.07	3,614	$$105K	SELL
21:00:05	$29.07	2,400	$$70K	SELL
21:00:05	$29.07	2,505	$$73K	SELL
21:00:00	$29.07	1,411	$$41K	BUY

5 dark pool trades shown · $$2.7M preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

What Traders Are Saying About ZYME

1 posts

SEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for ZYME. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.

Nicole AdamsVERIFIED30d ago

88 views

Join 3,500+ traders discussing ZYME in real-time

Trade ideas, setups, dark pool alerts, and AI-powered analysis

Join the discussion

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Zymeworks Inc. (ZYME) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

ZYME — frequently asked questions

What is ZYME stock price today?

Zymeworks Inc. (ZYME) is at $28.45, down 2.13% (-$0.62) at the Nov 12, 2026 close.

Why is ZYME stock moving today?

Latest ZYME news — Nov 11, 2026: Citigroup keeps Buy rating on Zymeworks, lifts target to $44 · Nov 10, 2026: TD Cowen keeps Buy rating on Zymeworks, lifts price target to $39

What is the ZYME price target?

The average analyst price target for ZYME is $39.00, ranging from $32 to $55, based on 7 analysts. Latest: Truist Securities maintains on Oct 28, 2026.

What do analysts rate ZYME?

Analyst ratings for ZYME: 14 Buy, 0 Hold, 0 Sell — consensus Strong Buy.

Did ZYME beat earnings?

ZYME last reported on Aug 6, 2026: EPS -$0.62 vs -$0.57 expected — a miss of 7.9%.

Does ZYME pay a dividend?

ZYME does not currently pay a dividend.

What are ZYME support and resistance levels?

Support: $28.40, $27.02, $24.60. Resistance: $30.18, $31.49, $34.04.

What are insiders doing with ZYME?

Insider activity: SELLING, 0 buys and 5 sells in the last 90 days.

What is the latest news on ZYME?

Nov 11, 2026: Citigroup keeps Buy rating on Zymeworks, lifts target to $44 · Nov 10, 2026: TD Cowen keeps Buy rating on Zymeworks, lifts price target to $39 · Nov 10, 2026: Truist Securities keeps Buy rating on Zymeworks, lifts target to $36